- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00357747
AEG35156 and Docetaxel in Treating Patients With Solid Tumors
A Phase I Study of AEG35156 in Combination With Docetaxel in Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. AEG35156 may help docetaxel work better by making tumor cells more sensitive to the drug.
PURPOSE: This phase I trial is studying the side effects and best dose of AEG35156 when given together with docetaxel in treating patients with solid tumors.
Study Overview
Status
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Determine the maximum tolerated dose and define the recommended phase II dose of AEG35156 in combination with docetaxel in patients with solid tumors.
Secondary
- Determine the qualitative and quantitative toxicities of AEG35156 and docetaxel and define duration and reversibility of those toxicities.
- Determine the pharmacokinetic profile of this regimen.
- Assess, preliminarily, the antitumor activity of this regimen in patients with measurable disease.
- Assess the pharmacodynamic effects of AEG35156 administration on X-linked inhibitor of apoptosis protein (XIAP) levels and apoptosis in peripheral blood mononuclear cells and, in selected patients, in tumor tissue.
- Evaluate M30/M65 cytokeratin 18 level, a marker of apoptosis/necrosis of epithelial tumors, in these patients.
OUTLINE: This is a multicenter, open-label, dose-escalation study of AEG35156.
Patients receive AEG35156 IV continuously on days -2 and -1. Patients then receive AEG35156 IV continuously over 24 hours on days 1, 8, and 15. Beginning with course 2, patients also receive docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of AEG35156 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Blood is collected at baseline and periodically during study treatment for pharmacokinetic and pharmacodynamic assessment.
After completion of study treatment, patients are followed at 4 weeks and then every 3 months thereafter.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BCCA - Vancouver Cancer Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Univ. Health Network-Princess Margaret Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1S6
- McGill University - Dept. Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
DISEASE CHARACTERISTICS:
Histologically confirmed solid tumor
- Locally advanced, metastatic, or recurrent disease that is refractory to standard curative therapy or for which no curative therapy exists
- Clinically and/or radiographically documented disease
- Docetaxel single-agent therapy must be a reasonable treatment option
No newly diagnosed CNS metastases
- Previously treated, intracranial disease that has been stable for ≥ 6 months allowed
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy ≥ 12 weeks
- Absolute granulocyte count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Bilirubin normal
- Creatinine normal
- AST and ALT ≤ 1.5 times upper limit of normal
- PT or INR normal
- PTT normal
- No known bleeding disorder
- No preexisting peripheral neuropathy ≥ grade 2
- No prior serious allergic reaction to taxanes (e.g., paclitaxel or docetaxel)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
No other serious illness or medical condition that would be aggravated by treatment or preclude study requirements, including any of the following:
- Serious uncontrolled infection
- Significant cardiac dysfunction
- Significant neurological disorder
PRIOR CONCURRENT THERAPY:
- No more than 2 prior chemotherapy regimens for metastatic or recurrent disease
- No more than 1 prior adjuvant chemotherapy regimen
- No more than 1 prior taxane-containing regimen
- At least 4 weeks since prior chemotherapy and recovered
- At least 4 weeks since prior external-beam radiotherapy provided < 30% of marrow-bearing areas are irradiated*
- At least 4 weeks since prior investigational agents or new anticancer therapy
- At least 2 weeks since prior hormonal therapy or immunotherapy
- At least 2 weeks since prior surgery and recovered
- No prior nephrectomy
No concurrent anticoagulant therapy in therapeutic doses
- Nontherapeutic dose anticoagulant therapy (e.g., 1 mg warfarin once daily) allowed
- No other concurrent experimental drugs or anticancer therapy
No other concurrent cytotoxic therapy or radiotherapy
- Small-volume, nonmyelosuppressive palliative radiotherapy allowed NOTE: *Exceptions are made for prior low-dose non-myelosuppressive radiotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AEG35156 plus docetaxel
|
After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and toxicity evaluated according to the NCI CTCAE version 3.0
Time Frame: Every 3 weeks
|
Every 3 weeks
|
|
Response and progression using RECIST criteria
Time Frame: Every 6 weeks
|
Every 6 weeks
|
|
Response duration measured from the time complete response or partial response (whichever is first recorded) is documented until the first date that recurrent or progressive disease is objectively documented
Time Frame: Every 3 months
|
After completion of protocol therapy, patients with PR/CR ongoing assessed q3 months until relapse.
|
Every 3 months
|
Stable disease duration measured from the time of start of therapy until the criteria for progression are met
Time Frame: Every 3 months
|
After completion of protocol therapy, patients with ongoing SD assess q 3months until progression.
|
Every 3 months
|
Pharmacokinetics
Time Frame: cycle 1 and 2
|
cycle 1 and 2
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Gerald Batist, MD, Jewish General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- I166
- CAN-NCIC-IND166 (Other Identifier: PDQ)
- CDR0000481440 (Other Identifier: PDQ)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unspecified Adult Solid Tumor, Protocol Specific
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingCollection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Kantonsspital GraubuendenUnknownUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificSwitzerland
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Vanderbilt UniversityNational Cancer Institute (NCI)TerminatedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedSirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyWithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid CancerUnited States
-
University of Texas Southwestern Medical CenterRecruitingUnspecified Adult Solid Tumor, Protocol SpecificUnited States
Clinical Trials on AEG35156
-
Aegera TherapeuticsTerminatedCarcinoma, Non-Small-Cell LungUnited States
-
Aegera TherapeuticsTerminatedHuman Mammary CarcinomaUnited States
-
Aegera TherapeuticsTerminated
-
Aegera TherapeuticsTerminatedLeukemiaUnited States, Canada, Germany
-
Aegera TherapeuticsTerminatedCarcinoma | PancreasUnited States
-
Aegera TherapeuticsThe Leukemia and Lymphoma SocietyTerminatedLymphoma, B-Cell | Leukemia, Lymphocytic, Chronic, B-CellCanada, United States
-
Aegera TherapeuticsChinese University of Hong KongCompletedAdvanced Hepatocellular CarcinomaChina
-
NCIC Clinical Trials GroupCompletedUnspecified Adult Solid Tumor, Protocol SpecificCanada